| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
coiled-coil domain containing 162, pseudogene | 0.890 | 0.154 |
|
phenotype | 0.100 | None | 1.000 | 5 | 4 | 2009 | 2018 | |||||||||
|
long intergenic non-protein coding RNA 1221 | 1.000 | 0.038 |
|
phenotype | 0.100 | None | 1.000 | 3 | 2 | 2016 | 2018 | |||||||||
|
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase | 0.427 | 0.885 |
|
phenotype | 0.100 | None | 1.000 | 3 | 4 | 2016 | 2018 | |||||||||
|
TMEM72 antisense RNA 1 |
|
phenotype | 0.100 | None | 1.000 | 2 | 2 | 2016 | 2018 | |||||||||||
|
MIR4435-2 host gene | 0.604 | 0.692 |
|
phenotype | 0.100 | None | 1.000 | 2 | 5 | 2012 | 2016 | |||||||||
|
inhibitor of carbonic anhydrase pseudogene | 0.890 | 0.231 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||
|
ribosomal protein L6 pseudogene 9 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||||
|
STARD4 antisense RNA 1 | 0.890 | 0.115 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | |||||||||
|
TSPOAP1, SUPT4H1 and RNF43 antisense RNA 1 | 0.792 | 0.346 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||
|
RAB11B antisense RNA 1 | 0.890 | 0.038 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||
|
NPHP3-ACAD11 readthrough (NMD candidate) | 0.663 | 0.577 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||
|
MEF2C antisense RNA 1 | 0.861 | 0.154 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||
|
HORMAD2 and MTMR3 antisense RNA 1 | 0.839 | 0.308 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||
|
serous ovarian cancer associated RNA | 0.821 | 0.231 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||
|
CSRP3 and E2F8 antisense RNA 1 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||||
|
CCDC26 long non-coding RNA | 0.647 | 0.615 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||
|
PSMA3 antisense RNA 1 | 0.931 | 0.154 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||
|
long intergenic non-protein coding RNA 1122 | 0.821 | 0.269 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||
|
cancer susceptibility 15 | 0.603 | 0.577 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||
|
solute carrier family 22 member 20, pseudogene |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2018 | 2018 | |||||||||||
|
Pvt1 oncogene | 0.495 | 0.731 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||
|
long intergenic non-protein coding RNA 1137 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | |||||||||||
|
CD36 molecule | 0.446 | 0.846 | 1.1E-60 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
THADA armadillo repeat containing | 0.686 | 0.500 | 4.6E-41 |
|
phenotype | 0.100 | None | 1.000 | 1 | 1 | 2016 | 2016 | ||||||||
|
RAS p21 protein activator 2 | 0.579 | 0.769 | 7.4E-31 |
|
phenotype | 0.100 | None | 1.000 | 2 | 3 | 2012 | 2016 |